Study of feline oral squamous cell carcinoma: Potential target for cyclooxygenase inhibitor treatment

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 76, Issue 4, 2007, Pages 245-250

  DiBernardi, Lisa ^a   Doré, Monique ^b   Davis, John A ^c   Owens, Jane G ^d   Mohammed, Sulma I ^e,f   Guptill, Carolyn F ^a   Knapp, Deborah W ^a,f  

^a PURDUE UNIVERSITY   (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c AMGEN INC   (United States)

^d ELANCO ANIMAL HEALTH   (United States)

^e PURDUE UNIVERSITY   (United States)

^f PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; PIROXICAM; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CAT; DRUG BLOOD LEVEL; DRUG HALF LIFE; IMMUNOHISTOCHEMISTRY; MOUTH CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CAT DISEASES; CATS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; IMMUNOHISTOCHEMISTRY; MOUTH NEOPLASMS; PIROXICAM;

FELIDAE;

EID: 34247177094     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2007.01.006     Document Type: Article

References (31)

1. Sudbo J., and Reith A. The evolution of predictive oncology and molecular-based therapy for oral cancer prevention. Int. J. Cancer 115 3 (2005) 339-345
2. Zweifel B.S., Davis T.W., Ornberg R.L., and Masferrer J.L. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors. Cancer Res. 62 22 (2002) 6706-6711
3. Dempke W., Rie C., Grothey A., and Schmoll H.J. Cyclooxygenase-2: a novel target for cancer chemotherapy?. J Cancer Res. Clin. Oncol. 127 (2001) 411-417
4. Pannone G., Bufo P., Caiaffa M.F., et al. Cyclooxygenase-2 expression in oral squamous cell carcinoma. Int. J. Immunopathol. Pharmacol. 17 3 (2004) 273-282
5. Terakado N., Shintani S., Yano J., et al. Overexpression of cyclooxygenase-2 is associated with radioresistance in oral squamous cell carcinoma. Oral Oncol. 40 4 (2004) 383-389
6. Schmidt B.R., Glickman N.W., DeNicola D.B., de Gortari A.E., and Knapp D.W. Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs. J. Am. Vet. Med. Assoc. 218 11 (2001) 1783-1786
7. Cuendet M., and Pezzuto J.M. The role of cyclooxygenase and lipoxygenase in cancer chemoprevention. Drug Metabol. Drug Interact. 17 1-4 (2000) 109-157
8. Boria P.A., Murry D.J., Bennett P.F., et al. Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs. J. Am. Vet. Med. Assoc. 224 3 (2004) 388-394
9. Knapp D.W., Glickman N.W., Widmer W.R., et al. Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer. Cancer Chemother. Pharmacol. 46 3 (2000) 221-226
10. Rao M., Yang W., Seifalian A.M., and Winslet M.C. Role of cyclooxygenase-2 in the angiogenesis of colorectal cancer. Int. J. Colorectal Dis. 19 1 (2004) 1-11
11. Sinicrope F.A. Targeting cyclooxygenase-2 for prevention and therapy of colorectal cancer. Mol. Carcinog. 45 6 (2006) 447-454
12. Smith L.P., and Thomas G.R. Animal models for the study of squamous cell carcinoma of the upper aerodigestive tract: a historical perspective with review of their utility and limitations. Part A. Chemically-induced de novo cancer, syngeneic animal models of HNSCC, animal models of transplanted xenogeneic human tumors. Int. J. Cancer 118 9 (2006) 2111-2122
13. K.W. Head, R.W. Else, R.R. Dubielzig, Tumors of the alimentary tract, in: D.J. Meuten (Ed.), Tumors in Domestic Animals, fourth ed., Blackwell Publishing Professional (formerly Iowa State Press, Ames, IA, 2002, pp. 425-427.
14. Withrow S.J. Tumors of the gastrointestinal system part A: cancer of the oral cavity. In: Withrow S.J., and MacEwen E.G. (Eds). Small Animal Clinical Oncology. third ed. (2001), W.B. Saunders Co., Philadelphia, PA 227-240
15. Hayes A., Scase T., Miller J., Murphy S., Sparkes A., and Adams V. COX-1 and COX-2 expression in feline oral squamous cell carcinoma. J Comp. Pathol. 135 2-3 (2006) 93-99
16. Beam S.L., Rassnick K.M., Moore A.S., and McDonough S.P. An immunohistochemical study of cyclooxygenase-2 expression in various feline neoplasms. Vet. Pathol. 40 5 (2003) 496-500
17. Fox L.E., MacEwen E.G., Kurzman I.D., et al. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of feline mammary adenocarcinoma-a multicenter randomized double-blind study. Cancer Biother. 10 2 (1995) 125-130 Erratum in: Cancer Biother. 10(3) (1995) 249
18. In: Plumb D.C. (Ed). Plumb's Veterinary Drug Handbook. fifth ed. (2005), Blackwell Publishing, PharmaVet Inc., Stockholm, WI 641-642
19. Heeb H.L., Chun R., Koch D.E., et al. Multiple dose pharmacokinetics and acute safety of piroxicam and cimetidine in the cat. J. Vet. Pharmacol. Ther. 28 5 (2005) 447-452
20. Heeb H.L., Chun R., Koch D.E., et al. Single dose pharmacokinetics of piroxicam in cats. J. Vet. Pharmacol. Ther. 26 4 (2005) 259-263
21. Kargman S.L., O'Neill G.P., Vickers P.J., Evans J.F., Mancini J.A., and Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res. 55 12 (1995) 2556-2559
22. Tremblay C., Dore M., Bochsler P.N., and Sirois J. Induction of prostaglandin G/H synthase-2 in a canine model of spontaneous prostatic adenocarcinoma. J. Natl. Cancer Inst. 91 16 (1999) 1398-1403
23. Dore M., Hawkins H.K., Entman M.L., and Smith C.W. Production of a monoclonal antibody against canine GMP-140 (P-Selectin) and studies of its vascular distribution in canine tissues. Vet. Pathol. 30 3 (1993) 213-222
24. Panara M.R., Renda G., Sciulli M.G., et al. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. J. Pharmacal. Exp. Ther. 290 1 (1999) 276-280
25. Guptill L., Slater L., Wu C.C., et al. Experimental infection of young specific pathogen-free cats with Bartonella henselae. J. Infec. Dis. 176 1 (1997) 206-216
26. Chu J., Lloyd F.L., Trifan O.C., Knapp B., and Rizzo M.T. Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer. Mol. Cancer Ther. 2 1 (2003) 1-7
27. Liu C.H., Chang S.H., Narko K., et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in trangenic mice. J. Biol. Chem. 276 21 (2001) 18563-18569
28. Song X., Lin H.P., Johnson A.J., et al. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J. Natl. Cancer Inst. 94 8 (2002) 585-591
29. Cuendet M., and Pezzuto J.M. The role of cyclooxygenase and lipoxygenase in cancer chemoprevention. Drug Metabol. Drug Interact 17 1-4 (2000) 109-157
30. Mohammed S.I., Khan K.N., Sellers R.S., et al. Expression of cyclooxygenase-1 and 2 in naturally-occurring canine cancer. Prostagland. Leukot. Essent. Fatty Acids 70 5 (2004) 479-483
31. Bertone H., Snyde L.A., and Moore A.S. Environmental and lifestyle risk factors for oral squamous cell carcinoma in cats. J. Vet. Intern. Med. 17 4 (2003) 557-562